PIERIS PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
We may voluntarily include a summary of information required by Form 10-K under this Item 16. We have elected not to include such summary information.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized**.**
| PIERIS PHARMACEUTICALS, INC. | ||
| March 29, 2024 | By: | /s/ Stephen S. Yoder |
|---|---|---|
| Stephen S. Yoder | ||
| Chief Executive Officer and President | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated below and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Stephen S. Yoder | President, Chief Executive Officer and | March 29, 2024 |
| Stephen S. Yoder | Director (Principal Executive Officer) | |
| /s/ Thomas Bures | Chief Financial Officer | March 29, 2024 |
| Thomas Bures | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ James Geraghty | Chairman of the Board of Directors | March 29, 2024 |
| James Geraghty | ||
| /s/ Michael Richman | Director | March 29, 2024 |
| Michael Richman | ||
| /s/ Maya R. Said, Sc.D. | Director | March 29, 2024 |
| Maya R. Said, Sc.D. | ||
| /s/ Peter Kiener, D.Phil. | Director | March 29, 2024 |
| Peter Kiener, D.Phil. | ||
| /s/ Christopher Kiritsy | Director | March 29, 2024 |
| Christopher Kiritsy | ||
| /s/ Ann Barbier, M.D., Ph.D. | Director | March 29, 2024 |
| Ann Barbier, M.D., Ph.D. | ||
| /s/ Matthew L. Sherman, M.D. | Director | March 29, 2024 |
| Matthew L. Sherman, M.D. | ||
PIERIS PHARMACEUTICALS, INC.
Table of Contents
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 00042) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2023 and 2022 | F-6 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.